Login / Signup

Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions.

James P FranciosiEdward B MougeyEvan S DellonCarolina Gutierrez-JunqueraSonia Fernandez-FernandezRajitha D VenkateshSandeep K Gupta
Published in: Journal of asthma and allergy (2022)
Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE.
Keyphrases
  • protein protein
  • small molecule
  • young adults
  • healthcare
  • current status
  • clinical practice
  • emergency department
  • genome wide
  • copy number
  • dna methylation
  • drug delivery